Interferon News and Research

RSS

Human coronaviruses cause processing body loss

Researchers continue to expand their knowledge of coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen. Now, a new study published on the preprint server bioRxiv in November 2020 describes a vital mechanism whereby the novel SARS-CoV-2 pathogen can restrict the human host response. In doing so, the study explores how this novel feature of SARS-CoV-2 works and how it results in a reshaping of the human host's immune response.

11 Nov 2020

MD Anderson presents positive clinical data from combination cancer therapies at SITC 2020

Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting & Pre-Conference Programs.

11 Nov 2020

How SARS-CoV-2 blocks immune response

An international research team has confirmed the mechanism by which the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). Their article titled, “SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling,” is published in the journal Proceedings of the National Academy of Sciences.

11 Nov 2020

Promising new antivirals target arboviruses and SARS-CoV-2: Nodosome inhibitors

A new study describes two promising small molecules that inhibit a host cell factor, called nucleotide binding oligomerization domain-containing protein 2 (NOD2), that inhibits the replication and spread of many arboviruses. This could lead to the development of broad-spectrum antivirals. The study's findings have been published on the preprint server bioRxiv*.

10 Nov 2020

Novel super-activating macrophage receptor could explain hyper-inflammation in severe COVID-19

Immunity is a curious thing. While essential in protecting the body against invading pathogens and foreign antigens, it can also turn against the body and trigger destructive immunological processes. A new study published on the preprint server bioRxiv* in November 2020 reports on the role played by hyperactive macrophages in a range of acute and chronic hyper-inflammatory conditions.

10 Nov 2020

Lupus Research Alliance announces the 2020 Lupus Innovation Awards

The Lupus Research Alliance proudly announced today the 2020 Lupus Innovation Awards. The projects represent a wide breadth of scientific exploration in lupus, probing the development and progression of lupus while pointing to potential treatment approaches.

10 Nov 2020

Immunotherapy drugs trigger inflammatory arthritis in subset of cancer patients

Since doctors began treating cancer patients with immunotherapy drugs called checkpoint inhibitors nearly a decade ago, they have observed that a subset of these patients experience a side effect that clinically looks like inflammatory arthritis.

10 Nov 2020

Exosome-mediated mRNA delivery generates broad immune response to multiple SARS-CoV-2 proteins

Recently, researchers from The Johns Hopkins University School of Medicine, Baltimore, MD, USA, and Capricor Therapeutics, Inc., Beverly Hills, CA, USA, described a new approach to SARS-CoV-2 vaccine development using exosomes to deliver mRNAs that encode the antigens from multiple structural proteins of the virus.

9 Nov 2020

Promising yeast-expressed SARS-CoV-2 vaccine candidate effective in mice

Researchers at the Texas Children's Hospital Center for Vaccine Development, USA, have published a report on the preprint server bioRxiv that describes a yeast-expressed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) protein, a key target of current vaccine development efforts.

9 Nov 2020

Translational study within SARS-CoV-2 infected cells opens up new therapeutic avenues

A recent study published on the preprint server bioRxiv in October 2020 shows what the protein translation process looks like in specific terms. In doing so, the study has provided new insights that might prove helpful in developing new therapies for COVID-19 patients.

9 Nov 2020

Majority of population likely has pre-existing immunity to SARS-CoV-2, claim researchers

A team of researchers has conducted a study suggesting that the majority of the global population is likely to have pre-existing T-cell immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic.

9 Nov 2020

Innate immunity key to limiting viral load in COVID-19 cases

As the coronavirus disease 2019 (COVID-19) pandemic continues to cause many difficulties for public health authorities, research is ongoing to understand how the virus can cause fatal effects on those infected and thereby suggest effective preventive and therapeutic measures against it.

8 Nov 2020

COVID-19 hospitalizations and deaths skew towards older males of non-European ancestry

A team of researchers recently investigated the genetic determinants of COVID-19 risk and severity in humans.

6 Nov 2020

Reducing the airborne transmission risk for SARS-CoV-2

Rapid Reviews: COVID-19 (RR:C19), an open-access overlay journal published by the MIT Press that accelerates peer review of COVID-19-related research preprints, is currently soliciting reviews of the following COVID-19 preprints.

6 Nov 2020

Pre-existing anti-IFN autoantibodies may worsen COVID-19 in lupus patients

“Our observations suggest that the presence of these autoantibodies may predispose SLE patients to infection with SARS-CoV-2 with a more severe presentation and represent an additional risk factor in this patient population,” write Sarthak Gupta and colleagues from the National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, Maryland.

5 Nov 2020

Children produce different antibodies in response to infection with new coronavirus

Children and adults produce different types and amounts of antibodies in response to infection with the new coronavirus, SARS-CoV-2, a new study from researchers at Columbia University Vagelos College of Physicians and Surgeons has found.

5 Nov 2020

Study reveals new mechanism underlying immune-cell activation

When antibody-producing immune cells encounter infectious pathogens for the first time, they engage a signal cascade to generate a massive activation signal within seconds.

5 Nov 2020

RNA-binding proteins may suppress antiviral defenses against SARS-CoV-2

Conducted by researchers in South Korea at the Institute for Basic Science and the International Vaccine Institute, a new study published on the preprint server bioRxiv in November 2020 describes the many host proteins that bind with the ribonucleic acid (RNA) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and regulate the replication of the virus.

4 Nov 2020

Eye's cornea can resist infection from novel coronavirus

New findings from researchers at Washington University School of Medicine in St. Louis suggest the eye's cornea can resist infection from the novel coronavirus.

3 Nov 2020

"Training" the immune system with β-glucan compound may improve immune recovery

Immunotherapies, such as checkpoint inhibitor drugs, have made worlds of difference for the treatment of cancer.Most clinicians and scientists understand these drugs to act on what's known as the adaptive immune system, the T cells and B cells that respond to specific threats to the body.

30 Oct 2020